The biotechnology company forecast fiscal 2027 revenue of $550 million to $560 million, a 21% increase at the midpoint. That is above Wall Street’s $548.6 million estimate, but below the 22% growth recorded in 2026. Evercore ISI analysts said investors had expected growth to accelerate after the stock’s sharp run-up.

The forecast includes $100 million from artificial-intelligence drug discovery, the analysts said, less than management’s earlier commentary about triple-digit order growth. Excluding that revenue, baseline growth would be 14%, they said. Twist’s projected gross margin of 52.5% to 53% for fiscal 2027 also fell short of estimates and raised questions about margins on AI-related business, according to the analysts.

For its fiscal fourth quarter, revenue increased 28% to $126.6 million, exceeding the FactSet analyst consensus of $123.5 million. Twist reported a net loss of $20.6 million, or 32 cents a share, compared with a loss of $27.1 million, or 45 cents a share, a year earlier.